- ASX
Volpara Health Technologies Ltd
Healthcare AU VHT
NoneAUD
-(-%)
Last update at 2024-06-24T06:45:02.418326Z
Day Range
52 Week Range
Fundamentals
- Previous Close -
- Market Cap291.26M
- VolumeNone
- P/E Ratio-
- Dividend Yield-%
- EBITDA-7.89700M
- Revenue TTM37.96M
- Revenue Per Share TTM0.15
- Gross Profit TTM 23.82M
- Diluted EPS TTM-0.04
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Analyst Recommendations
-
Volpara Health partners with Trees that Count to offset carbon emissions
1 year, 8 months ago -
1 year, 10 months ago
-
Volpara Health Technologies Limited (ASX:VHT): When Will It Breakeven?
1 year, 11 months ago -
Volpara announces expanded sponsorship of DenseBreast-Info.org at SBI 2023
1 year, 11 months ago
Financials
Income Statement
Balancesheet
Change in Cash
Total Operating Cash
Dividends Paid
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Income before tax | -10.65244M | -15.01441M | -17.39558M | -21.71395M | -11.25551M |
| Minority interest | - | - | - | - | - |
| Net income | -9.17439M | -15.28116M | -16.05435M | -19.82549M | -11.24401M |
| Selling general administrative | 12.45M | 11.39M | 11.51M | 11.59M | 2.92M |
| Selling and marketing expenses | 14.29M | 13.12M | 11.28M | 12.92M | 8.08M |
| Gross profit | 30.30M | 22.14M | 16.57M | 10.59M | 3.95M |
| Reconciled depreciation | 5.13M | 4.33M | 2.84M | 2.18M | 0.30M |
| Ebit | -10.29767M | -14.88057M | -17.26154M | -21.64181M | -11.19900M |
| Ebitda | -5.16522M | -10.55024M | -14.42578M | -19.45793M | -10.90213M |
| Depreciation and amortization | 5.13M | 4.33M | 2.84M | 2.18M | 0.30M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -10.29767M | -14.88057M | -17.26154M | -21.64181M | -12.74756M |
| Other operating expenses | 50.89M | 46.63M | 40.19M | 39.05M | 17.54M |
| Interest expense | 0.35M | 0.13M | 0.13M | 0.07M | 0.06M |
| Tax provision | -1.47805M | 0.27M | -1.34123M | -1.93700M | -0.01200M |
| Interest income | 0.17M | 0.16M | 0.57M | 0.70M | 0.41M |
| Net interest income | -0.18066M | 0.03M | 0.44M | 0.68M | 0.39M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -1.47805M | 0.27M | -1.34123M | -1.88847M | -0.01149M |
| Total revenue | 32.77M | 24.27M | 18.13M | 12.32M | 4.79M |
| Total operating expenses | 48.42M | 44.50M | 38.63M | 37.32M | 16.70M |
| Cost of revenue | 2.47M | 2.13M | 1.55M | 1.73M | 0.84M |
| Total other income expense net | -0.35477M | -0.13384M | -0.13403M | -0.07215M | 1.49M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -9.17439M | -15.28116M | -16.05435M | -19.86058M | -11.24401M |
| Net income applicable to common shares | -9.80100M | -16.44100M | -17.48800M | -20.37100M | -11.74100M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Total assets | 74.15M | 75.27M | 86.86M | 71.10M | 18.17M |
| Intangible assets | 23.44M | 23.85M | 24.94M | 17.56M | 0.34M |
| Earning assets | - | - | - | - | - |
| Other current assets | 1.00M | 0.66M | 0.41M | 0.38M | 0.39M |
| Total liab | 26.18M | 21.47M | 20.03M | 20.19M | 4.59M |
| Total stockholder equity | 47.97M | 53.81M | 66.83M | 50.91M | 13.58M |
| Deferred long term liab | - | 2.33M | 1.75M | 1.59M | 0.93M |
| Other current liab | 4.31M | 3.79M | 2.68M | 3.59M | 1.73M |
| Common stock | 171.55M | 168.69M | 165.87M | 136.57M | 80.57M |
| Capital stock | 171.55M | 168.69M | 165.87M | 136.57M | 80.57M |
| Retained earnings | -127.04577M | -117.38730M | -101.03461M | -90.21449M | -69.15150M |
| Other liab | - | 0.29M | 1.14M | 1.64M | 0.02M |
| Good will | 20.21M | 17.96M | 17.68M | 8.02M | - |
| Other assets | 3.84M | 2.42M | 1.83M | 1.59M | 0.94M |
| Cash | 11.90M | 16.86M | 29.59M | 30.59M | 13.77M |
| Cash and equivalents | - | - | 2.00M | 0.00000M | 1.75M |
| Total current liabilities | 24.74M | 19.43M | 16.32M | 15.51M | 4.45M |
| Current deferred revenue | 18.91M | 13.91M | 10.50M | 10.46M | 2.07M |
| Net debt | -9.95132M | -14.56083M | -24.65437M | -26.92210M | -13.53285M |
| Short term debt | 0.51M | 0.53M | 2.27M | 0.59M | 0.12M |
| Short long term debt | - | - | 1.83M | - | 0.12M |
| Short long term debt total | 1.95M | 2.30M | 4.93M | 3.67M | 0.24M |
| Other stockholder equity | 0.00000M | 2.69M | 2.18M | -0.03510M | 0.00000M |
| Property plant equipment | 2.28M | 2.79M | 3.41M | 4.55M | 0.55M |
| Total current assets | 24.39M | 28.29M | 39.43M | 39.53M | 16.40M |
| Long term investments | 0.38M | 0.33M | - | - | - |
| Net tangible assets | - | 12.90M | 26.37M | 25.99M | 13.83M |
| Short term investments | 5.40M | 0.28M | 24.36M | 27.70M | 10.27M |
| Net receivables | 10.23M | 8.80M | 7.91M | 7.35M | 2.20M |
| Long term debt | - | 0.00000M | 0.45M | - | 0.13M |
| Inventory | 1.27M | 1.69M | 0.05M | 0.05M | 0.03M |
| Accounts payable | 1.01M | 1.19M | 0.87M | 0.86M | 0.52M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 3.47M | 2.50M | 2.00M | 4.59M | 2.17M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 165.87M | 136.57M | 80.57M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 2.88M | 2.17M | 1.61M | 1.55M | 0.90M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 49.75M | 46.98M | 47.43M | 31.56M | 1.77M |
| Capital lease obligations | 1.95M | 2.30M | 2.66M | 3.67M | 0.24M |
| Long term debt total | 1.53M | 1.91M | 2.90M | 3.16M | 0.13M |
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Investments | 2.75M | 15.50M | 2.35M | -16.59900M | -8.76900M |
| Change to liabilities | 0.00000M | 3.79M | 0.85M | 6.61M | 2.01M |
| Total cashflows from investing activities | 2.94M | 13.20M | -23.10500M | -39.31500M | -9.46300M |
| Net borrowings | - | -0.53600M | 2.22M | -0.29000M | -0.08700M |
| Total cash from financing activities | 0.50M | -0.02324M | 38.44M | 53.85M | 19.82M |
| Change to operating activities | - | -0.83800M | -0.50600M | -0.60300M | -0.62600M |
| Net income | -9.17439M | -15.28116M | -16.05435M | -19.82549M | -11.24401M |
| Change in cash | 0.03M | 1.68M | 3.86M | -0.42800M | 0.74M |
| Begin period cash flow | 9.06M | 7.32M | 3.37M | 4.01M | 3.20M |
| End period cash flow | 9.09M | 8.99M | 7.23M | 3.58M | 3.94M |
| Total cash from operating activities | -9.17439M | 4.33M | -12.87157M | -15.55816M | -10.64200M |
| Issuance of capital stock | 1.05M | 0.47M | 37.86M | 57.18M | 20.84M |
| Depreciation | 2.86M | 4.33M | 2.84M | 2.18M | 0.30M |
| Other cashflows from investing activities | 5.51M | 15.37M | -22.27800M | -38.98600M | -8.76900M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | 0.00200M | -0.01400M | -0.01800M |
| Change to account receivables | - | -0.48100M | -1.34200M | -2.96500M | -1.09100M |
| Sale purchase of stock | 1.12M | 0.51M | -1.46975M | -3.04377M | -0.93852M |
| Other cashflows from financing activities | -0.55134M | -0.49819M | 2.04M | -0.28273M | -0.08332M |
| Change to netincome | - | -2.04500M | 1.38M | -1.53100M | 0.51M |
| Capital expenditures | 2.40M | 2.02M | 0.76M | 0.98M | 0.66M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 0.47M | 0.37M | 1.57M | 1.40M | 1.04M |
| Stock based compensation | - | - | - | - | - |
| Other non cash items | 9.17M | 10.95M | 13.22M | 17.68M | 10.95M |
| Free cash flow | -11.57821M | 2.31M | -13.63077M | -16.54187M | -10.85616M |
Peer Comparison
Sector: Healthcare Industry: Health Information Services
| Company | Change (AUD) | Price (AUD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| VHT Volpara Health Technologies Ltd |
- -% | - | - | - | 7.65 | 6.53 | 7.78 | -60.9831 |
| PME Pro Medicus Ltd |
-12.96 6.39% | 189.77 | 204.96 | 120.48 | 107.88 | 95.29 | 113.84 | 149.57 |
| CGS CogState Ltd |
-0.015 1.07% | 1.39 | 27.80 | 20.58 | 5.06 | 3.43 | 2.72 | 11.95 |
| ONE Oneview Healthcare PLC |
-0.045 15.52% | 0.24 | - | - | 22.77 | 10.26 | 12.46 | -3.5247 |
| ALC Alcidion Group Ltd |
-0.003 3.90% | 0.07 | - | 4.97 | 2.93 | 1.21 | 2.72 | 53.70 |
Reports Covered
Profile
Volpara Health Technologies Limited provides breast imaging analytics software products in New Zealand. The company offers Volpara Analytics, a software that optimize breast cancer screening operations; Volpara Live, which provides instant patient-based image quality feedback; Volpara Lung, a patient management software that streamlines lung screening workflow; and Volpara Patient Hub, a customizable mammography reporting and patient communications software. It also offers Volpara Risk, an integration with Patient Hub that uses TC8 to calculate patients' risk of developing breast cancer; Volpara Risk Pathways, a program for identifying and managing high-risk breast, lung, ovarian, and colorectal cancer screening patients; Volpara Scorecard, which displays patient breast density and risk insights essential for improved clinical decision-making and early detection; and Volpara Science, an AI-based software that powers Volpara software products; and Volpara Thumbnail, an image-enhanced patient notification letters. In addition, the company provides TruDensity, a Volpara clinical function; TruPGMI, a Volpara clinical function, which uses artificial intelligence to automatically and objectively assess the positioning of the patient and resulting image quality; TruPressure, a Volpara clinical function, which determines whether the compression pressure applied by the radiographer is in the sweet spot that yields quality images, minimal radiation exposure, and the least discomfort; and TruRadDose, a Volpara clinical function which analyses the radiation dose delivered to patients based on their breast density. It operates in North America, the Asia Pacific, Europe, the Middle East, and Africa. Volpara Health Technologies Limited has a strategic relationship with RevealDx. The company was incorporated in 2009 and is headquartered in Wellington, New Zealand. As of May 13, 2024, Volpara Health Technologies Limited operates as a subsidiary of Lunit Inc..
Volpara Health Technologies Ltd
40 Mercer Street, Wellington, New Zealand, 6011
- 64 4 499 6029
- Employees : 156
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Ralph P. Highnam B.Sc., M.Sc., Ph.D. | Founder, MD, Chief Scientist & Chief Science and Innotion Officer | NA |
| Mr. Craig Hadfield | CFO & Company Sec. | NA |
| Ms. Teri Thomas | CEO, MD & Director | NA |
| Prof. Nico Karssemeijer | Co-Founder & Member of Scientific Board | NA |
| Mr. Tana Isaac | Exec. VP of Product & Technology | NA |
| Mr. Gareth Beaumont | Chief Information Officer & Chief Information Security Officer | NA |
| Mr. Fred Struve B.Sc., J.D. | Joint Company Sec. & Gen. Counsel | NA |
| Ms. Jill Spear | Exec. VP of Sales & Marketing | NA |
| Ms. Kathryn Greene | Chief People Officer | NA |
| Mr. Julian Marshall | Chief Knowledge Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
